| Name: |
ETOMIDATE (AmidateR) |
| Classification: |
sedative-hypnotic
- used as induction agent for intubation as general sedative or in rapid sequence induction
- rapid onset of action usually within 60 seconds (may be 5-15 seconds) with duration of action of 3-5 minutes (may be up to 14 minutes)
- no analgesic activity; minimal respiratory or cardiovascular effects
- special access product
|
| Dose: |
- 0.3 mg/kg to usual maximum of 20 mg IV
- may require dose reduction in elderly patients
|
| Administration: |
IV direct over 30-60 seconds
- use large proximal arm veins or central line if possible to avoid pain on injection
|
| Adverse Effects: |
- injection site pain
- transient skeletal muscle movements including myoclonus
- hypo-/hyperventilation, apnea
- arrhythmias
- laryngospasm
- nausea/vomiting
- prolonged suppression of cortisol and aldosterone synthesis with continuous infusion or repeated dosing
|
| Monitoring Therapy: |
- continuous heart rate and rhythm
- blood pressure
- respiratory rate
- Oxygen saturation
- End-tidal CO2
|
| Adult Critical Care Protocol: |
- Must be administered by MD trained in airway management with patient specific approval from senior resident or CCTC consultant.
- monitoring sheet must be completed by administering physician and returned to Pharmacy Department.
|
